dpp4i and glp 1 GLP-1 receptor agonist versus DPP-4 inhibitor kidney and cardiovascular outcomes in clinical practice in type-2 diabetes Full article: Revolutionizing Treatment Strategies

By combining therapeutic development with delivery innovation, SureNano Science is building a vertically integrated metabolic disease platform rather than focusing solely on a single injectable drug candidate

The study published in JAMA Psychiatry found that patients with alcohol use disorder (AUD) who were prescribed GLP-1 drugs, popularly known by their brand names Ozempic and Wegovy, had a significantly lower risk of hospitalization for alcohol-related issues

Time will tell

Lixisenatide In a QT study, HR data from serial ECG measurements in healthy individuals receiving lixisenatide 20 g QD for 28 days (N = 68

Non-NHL controls, used as negative ground truth in the AI training, comprised of 60% inflammatory liver diseases, 15% non-NHL tumors, 15% normal biopsies, and 10% other diagnoses

In a phase 2b randomized clinical trial, bofanglutide demonstrated a strong efficacy in reducing blood sugar in people with type 2 diabetes